K. Nathan Sankar

Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy

Gaopeng Li, Jae Eun Choi, Ilona Kryczek et al. · Cancer Cell · 2023 · 147 citations · Full text

Medicine, Immunology, Oncology +14

Real World Outcomes versus Clinical Trial Results of Durvalumab Maintenance in Veterans with Stage III Non-Small Cell Lung Cancer

K. Nathan Sankar, Alex K. Bryant, Garth W. Strohbehn et al. · Cancers · 2022 · 44 citations · Full text

Medicine, Oncology, Chemotherapy +13

Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study

Amin H. Nassar, So Yeon Kim, Jacqueline V. Aredo et al. · Journal of Thoracic Oncology · 2024 · 39 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Prognostic and predictive value of neutrophil-to-lymphocyte ratio with adjuvant immunotherapy in stage III non-small-cell lung cancer

Alex K. Bryant, K. Nathan Sankar, Garth W. Strohbehn et al. · Lung Cancer · 2021 · 36 citations · Full text

Life Sciences, Immunology, Oncology +17

Interim results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager, in patients (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN).

Himisha Beltran, Afshin Dowlati, Prantesh Jain et al. · Journal of Clinical Oncology · 2024 · 29 citations

Medicine, Oncology, Pharmacology +17